Rimonabant: New data and emerging experience

Current Atherosclerosis Reports

Volumn 10, Issue 1, 2008, Pages 71-78

  Wright, Suzanne M ^a   Dikkers, Carolien ^b   Aronne, Louis J ^b  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ANANDAMIDE; ANTIDEPRESSANT AGENT; C REACTIVE PROTEIN; CANNABINOID; CANNABINOID 1 RECEPTOR; CANNABINOID 1 RECEPTOR ANTAGONIST; GLUCOSE; LOW DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; PLACEBO; RIMONABANT; SIBUTRAMINE; SULFONYLUREA; TETRAHYDROLIPSTATIN; TRIACYLGLYCEROL;

ANXIETY DISORDER; ASTHENIA; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTUSION; DEPRESSION; DIABETES MELLITUS; DIARRHEA; DIZZINESS; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG MECHANISM; DRUG RESPONSE; DRUG SAFETY; DRUG WITHDRAWAL; FATIGUE; FOOD INTAKE; GASTROENTERITIS; GASTROINTESTINAL DISEASE; GLYCEMIC CONTROL; HEADACHE; HOT FLUSH; HUMAN; INFLUENZA; INSOMNIA; IRRITABILITY; LIPID METABOLISM; LIPOGENESIS; MENTAL DISEASE; METABOLIC DISORDER; METABOLIC REGULATION; MONOTHERAPY; MOOD CHANGE; NAUSEA; NEUROLOGIC DISEASE; NONHUMAN; OBESITY; REVIEW; RISK BENEFIT ANALYSIS; SIDE EFFECT; VOMITING; WEIGHT REDUCTION;

ADIPOSE TISSUE; ANIMALS; CARDIOVASCULAR DISEASES; CHOLESTEROL, HDL; ENDOCANNABINOIDS; HUMANS; OBESITY; PIPERIDINES; PYRAZOLES; RECEPTOR, CANNABINOID, CB1; RECEPTORS, CANNABINOID; RISK FACTORS;

EID: 40749128829     PISSN: 15233804     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11883-008-0011-5     Document Type: Review

References (34)

1. Ogden CL, Carroll MD, Curtin LR, et al.: Prevalence of overweight and obesity in the United States, 1999-2004. JAMA 2006, 295:1549-1555.
2. Jolliffe D: Extent of overweight among US children and adolescents from 1971 to 2000. Int J Obes Relat Metab Disord 2004, 28:4-9.
3. Reaven G: The metabolic syndrome or the insulin resistance syndrome? Different names, different concepts, and different goals. Endocrinol Metab Clin North Am 2004, 33:283-303.
4. Mokdad AH, Marks JS, Stroup DF, Gerberding JL: Actual causes of death in the United States, 2000. JAMA 2004, 291:1238-1245.
5. Beckley E: New ADA initiative moved beyond "metabolic syndrome." Cardiometabolic risk proposed as umbrella term for diabetes risk factors. DOC News 2006, 3:1-3.
6. Rodriguez de Fonseca F, Del Arco I, Bermudez-Silva FJ, et al.: The endocannabinoid system: physiology and pharmacology. Alcohol Alcohol 2005, 40:2-14.
7. Matsuda LA, Lolait SJ, Brownstein MJ, et al.: Structure of a cannabinoid receptor and functional expression of the cloned cDNA. Nature 1990, 346:561-564.
8. Munro S, Thomas KL, Abu-Shaar M: Molecular characterization of a peripheral receptor for cannabinoids. Nature 1993, 365:61-65.
9. Piomelli D, Giuffrida A, Calignano A, Rodríguez de Fonseca F: The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol Sci 2000, 21:218-224.
10. Engeli S, Böhnke J, Feldpausch M, et al.: Activation of the peripheral endocannabinoid system in human obesity. Diabetes 2005, 54:2838-2843.
11. Bluher M, Engeli S, Kloting N, et al.: Dysregulation of the peripheral and adipose tissue endocannabinoid system in human abdominal obesity. Diabetes 2006, 55:3053-3060.
12. Cota D, Marsicano G, Tschop M, et al.: The endogenous cannabinoid system affects energy balance via central orexigenic drive and peripheral lipogenesis. J Clin Invest 2003, 112:323-326.
13. Pagotto U, Marsicano G, Cota D, et al.: The emerging role of the endocannabinoid system in endocrine regulation and energy balance. Endocr Rev 2006, 27:73-100.
14. Ravinet Trillou C, Arnone M, Delgorge C, et al.: Anti-obesity effect of SR141716, a CB1 receptor antagonist, in diet-induced obese mice. Am J Physiol Regul Integr Comp Physiol 2003, 284:R345-353.
15. Di Marzo V, Matias I: Endocannabinoid control of food intake and energy balance. Nat Neurosci 2005, 8:585-589.
16. Bensaid M, Gary-Bobo M, Esclangon A, et al.: The cannabinoid CB1 receptor antagonist SR141716 increases Acrp30 mRNA expression in adipose tissue of obese fa/fa rats and in cultured adipocyte cells. Mol Pharmacol 2003, 63:908-914.
17. Pischon T, Girman CJ, Hotamisligil GS, et al.: Plasma adiponectin levels and risk of myocardial infarction in men. JAMA 2004, 291:1730-1737.
18. Liu YL, Connoley IP, Wilson CA, Stock MJ: Effects of the cannabinoid CB1 receptor antagonist SR141716 on oxygen consumption and soleus muscle glucose uptake in Lep(ob)/Lep(ob) mice. Int J Obes (Lond) 2005, 29:183-187.
19. Osei-Hyiaman D, DePetrillo M, Pacher P, et al.: Endocannabinoid activation at hepatic CB1 receptors stimulates fatty acid synthesis and contributes to diet-induced obesity. J Clin Invest 2005, 115:1298-1305.
20. FDA Rimonabant Hearing June 13, 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/slides/ 2007-4306s1-04-Sanofi-Aventis-Rosenzweig.pdf. Accessed on October 2, 2007.
21. Van Gaal LF, Rissanen AM, Scheen AJ, et al.: Effects of the cannabinoid-1 receptor blocker rimonabant on weight reduction and cardiovascular risk factors in overweight patients: 1-year experience from the RIO-Europe study. Lancet 2005, 365:1389-1397.
22. Despres JP, Golay A, Sjostrom L: Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia. N Engl J Med 2005, 353:2121-2134.
23. Pi-Sunyer FX, Aronne LJ, Heshmati HM, et al.: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA 2006, 295:761-775.
24. Scheen AJ, Finer N, Hollander P, et al.: Efficacy and tolerability of rimonabant in overweight or obese patients with type 2 diabetes: a randomised controlled study. Lancet 2006, 368:1660-1672.
25. SERENADE confirms efficacy of rimonabant in diabetes. Available at http://www.emea.eu.int/humandocs/Humans/EPAR/acomplia/acomplia.htm. Accessed on August 10, 2007.
26. Henness S, Robinson DM, Lyseng-Williamson KA: Rimonabant. Drugs 2006, 66:2109-2119; discussion 2120-2121.
27. FDA Rimonabant Hearing, June 13, 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/slides/ 2007-4306s1-08-Sanofi-Aventis-backup-slides.pdf. Accessed on August 14, 2007.
28. Padwal R, Li SK, Lau DC: Long-term pharmacotherapy for overweight and obesity: a systematic review and meta-analysis of randomized controlled trials. Int J Obes Relat Metab Disord 2003, 27:1437-1446.
29. EMEA: Scientific Discussion Accomplia. Scientific Review of Accomplia. Available at http://www.emea.eu.int/human-docs/Humans/ EPAR/acomplia/acomplia.htm. Accessed on August 10, 2007.
30. FDA Rimonabant Hearing, June 13, 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/slides/ 2007-4306s1-05-Sanofi-Aventis-Chew.pdf. Accessed on August 9, 2007.
31. ZIMULTI (rimonabant) NDA 21-888, Briefing Information for FDA Advisory Committee Meeting. Available at http://www.fda.gov/ohrms/ dockets/ac/07/briefing/2007-4306b1-01-sponsor-backgrounder.htm. Accessed on August 30, 2007.
32. Acomplia drug patients at psychiatric risk. Available at http://www.telegraph.co.uk/news/main.jhtml?xml=/news/2007/07/20/ nweight120.xml. Accessed on August 10, 2007.
33. FDA Rimonabant Hearing, June 13, 2007. Available at http://www.fda.gov/ohrms/dockets/ac/07/slides/ 2007-4306s1-10-FDA-Egan_files/frame.htm. Accessed on August 5, 2007.
34. EMEA press release, July 19, 2007. Available at http://www.emea.europa.eu/humandocs/PDFs/EPAR/acomplia/32982607en.pdf. Accessed on August 10, 2007.